Read more
13:21 · 13 October 2023

Novo Nordisk surges after higher Q3 earnings forecasts

-
-
Open account Download free app

Novo Nordisk (NOVOB.DK) shares are gaining 3.0% after the company raised its sales forecast for 2023 on strong demand for Ozempic and Wegovy medicines.

  • Operating profit at constant exchange rates +40% to +46%, previously expected +31% to +37%, Bloomberg estimated +37.5% 
  • Sales at constant exchange rates +32% to +38%, previously expected +27% to +33%, Bloomberg estimated +31.7%.
11 February 2026, 08:47

NFP preview

11 February 2026, 08:30

Economic calendar: NFP data and US oil inventory report 💡

10 February 2026, 18:47

Daily summary: Weak US data drags markets down, precious metals under pressure again!

10 February 2026, 18:01

Datadog in Top Form: Record Q4 and Strong Outlook for 2026

This content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.

Join over 2 Million investors from around the world